Clinical study for the treatment of Dyskinesia in Cerebral Palsy available at Rare Disease Research

At Rare Disease Research we are conducting the RECLAIM-DCP clinical study investigating the safety and efficacy of orally administered Deutetrabenazine to reduce the severity of dyskinetic involuntary movements associated with Cerebral Palsy.  

Contact us if you are interested in learning more about this study and if you meet the following requirements: 

  • Diagnosis of DCP
  • Children and adolescents, 6 through 18 years of age
  • Weight of at least 26 pounds (12 kg)
  • CP symptoms since infancy (≤2 years) 
  • Predominant disorder is of choreiform nature (abrupt involuntary movements) 

For additional study specific information visit Visit our Active Trials section for general information about Cerebral Palsy. You can also contact us directly.

Contact us

You can also contact us directly at: 
678 - 883 - 6897